文献速递区域麻醉与超声疼痛医学

肾上腺素对TAP阻滞中罗哌卡因药代动力学的影响:一项随机对照试验

Impact of epinephrine on ropivacaine pharmacokinetics in TAP blocks: a randomized controlled trial.
PubMed 文献 · Reg Anesth Pain Med · 2026-08-05

该随机对照试验纳入40例腹腔镜结肠切除术患者,比较罗哌卡因单用与联合肾上腺素(1:200 000;5 µg/mL)行双侧TAP阻滞的药代动力学。结果显示肾上腺素未改变罗哌卡因Cmax,但显著延长Tmax并降低平均血浆浓度,支持TAP阻滞中常规加入肾上腺素。

要点

  • 肾上腺素未显著改变TAP阻滞中罗哌卡因的Cmax。
  • 肾上腺素显著延长Tmax(165 vs 55.9 min,p<0.001)。
  • 两组均观察到QT间期延长,无严重不良事件。

核心结论

  • TAP阻滞中加入肾上腺素不改变罗哌卡因Cmax,但延长达峰时间,支持常规加入肾上腺素。

研究设计与样本

  • 随机对照试验,40例腹腔镜结肠切除术患者接受双侧TAP阻滞,罗哌卡因剂量1 mg/kg,分为单用组与联合肾上腺素组(1:200 000;5 µg/mL)。

主要发现

  • TAP/E+组平均Cmax为0.531±0.245 µg/mL,TAP/E-组为0.746±0.428 µg/mL,差异无统计学意义。
  • 肾上腺素显著延长Tmax(165 vs 55.9 min,p<0.001)并降低Cmean(p=0.005)。
  • 两组均未发生严重不良事件,但均观察到QT间期延长。

临床怎么用

  • 基于本试验结果,TAP阻滞中可常规加入肾上腺素以延长罗哌卡因达峰时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ropivacaine is commonly used in abdominal wall blocks due to its safety profile, and the addition of epinephrine is hypothesized to prolong analgesic duration and reduce systemic absorption. However, previous studies have been limited by non-weight-adjusted dosing and potential pharmacokinetic interactions, and inadequate investigation of the free form of ropivacaine. OBJECTIVE: To characterize and compare the pharmacokinetics of total and free ropivacaine administered at a weight-adjusted dose of 1 mg/kg in Transversus Abdominis Plane (TAP) blocks, with and without epinephrine (1:200 000; 5 µg/mL). METHODS: In this randomized controlled trial, 40 patients undergoing laparoscopic colectomy received bilateral TAP blocks with ropivacaine alone (TAP/E-) or ropivacaine with epinephrine (TAP/E+). Pharmacokinetic parameters, including maximum plasma concentration (Cmax), time to Cmax (Tmax), and area under the concentration-time curve, were assessed over 240 min. Secondary outcomes included α₁-acid glycoprotein (AGP), analgesia, safety, and mean plasma concentration (Cmean). RESULTS: The mean Cmax in the TAP/E+ group (0.531±0.245 µg/mL) was not significantly different from that in the TAP/E- group (0.746±0.428 µg/mL). Epinephrine significantly prolonged Tmax (165 vs 55.9 min in TAP/E-, p<0.001) and reduced Cmean (p=0.005). No serious adverse events occurred, though QT interval prolongation was observed in both groups. CONCLUSION: This study demonstrates that adding epinephrine did not alter the Cmax of ropivacaine in TAP blocks, but did prolong the time to reach Cmax. These findings support the routine inclusion of epinephrine in TAP blocks and provide a basis for multimodal analgesia strategies. TRIAL REGISTRATION NUMBER: NCT04959123.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Rozier R, Le Guennec Y, Capdevila X, et al. Impact of epinephrine on ropivacaine pharmacokinetics in TAP blocks: a randomized controlled trial. Reg Anesth Pain Med. 2026. PMID: 40096993. doi:10.1136/rapm-2025-106500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。